Navigating Treatment Options in Low-Risk Myelodysplastic Syndromes
This video explores the current treatment landscape for lower-risk MDS patients, including the various agents and sequencing strategies employed to best optimize outcomes.
With advances in the understanding of myelodysplastic syndromes (MDS), both in the pathogenesis and biology of the disease, and with newer treatments and methods of supportive care, survival of patients with MDS has markedly improved.
In this video, Valeria Santini, MD, of the University of Florence in Italy, explores the current treatment landscape for lower-risk MDS patients, including the various agents and sequencing strategies employed to best optimize outcomes.
Santini also discusses treatment decisions based on molecular alterations and when experimental therapies might be most appropriate.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
